Organizing Pneumonia in Hospitalized COVID-19 Patients: Risk Factors and Long-term Outcomes
Background of Organizing Pneumonia in Hospitalized COVID-19 Patients:
Some patients develop post-COVID organizing pneumonia (OP), which is responsive to treatment with corticosteroids. This multicenter, case-control study of patients hospitalized for COVID19 sought to determine the prevalence, risk factors, radiological outcomes, and evolution after treatment.
Methods:
We included 153 consecutive patients with OP and 140 without OP whorequired hospitalization because of COVID. OP patients were followed up for 12-months, with visitsat 1, 3, 6, and 12 months after hospital discharge.
Results:
Risk Factors for Organizing Pneumonia in COVID-19 Patients
Risk factors for OP at hospital admission were advanced age, previous respiratory disease, and elevated C-reactive protein levels. Follow-up CT scans performed one year after admission showed progressive improvement in radiological involvement; however up to 57% of patients with OP remained with fibrotic-like changes.Multivariate analysis showed a significant association of fibrotic pattern with older age, high dose of corticosteroids, and extensive parenchymal lung involvement on admission CT scans.
Conclusions:
Following post-COVID OP, fibrotic-like changes may persist over the long term. Treatment with high-dose corticosteroids appears to be associated with higher mortality.This abstract is funded by: financed by FEDER Funds (PI19/01152), SEPAR, SOCAP, FUCAP, Beca Mecenatge Clinic and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). It did not receive any other grants from funding agencies in the public, commercial, or not-for-profit sectors.
Authors:
J. Sellares Torres, S. Cuerpo, F. Hernandez-Gonzalez, M. Benegas, N. Albacar Ingla, A.Lopez-Giraldo, I. Cobo, S. Suarez, V. Torres, A. Salazar, N. Soler, M. B. Noboa-Sevilla, A.D. Frino-Garcia, N. Perez-Rodas, J. Francesqui Candela, X. Alsina-Restoy, A. Muñoz-Fernandez, N. Roger, S. Prieto, A. Vlagea11, E. Ruiz11, M. Faner, J. A. Barbera, A.Soriano, J. Badia, M. Molina-Molina, O. Sibila, M. Sanchez, A. Agusti, J. GarciaAymerich.
Read more details at
Noticias relacionadas
Entrevista SEMG al Dr. Alvar Agusti, Experto en la II Jornada Resprimaria
Descubre los avances en el diagnóstico y tratamiento de la EPOC con el Dr. Alvar Agustí en la II Jornada SEMG Resprimaria. Conoce la importancia de la espirometría, la detección precoz y las nuevas estrategias terapéuticas.
Monitoring and assessment of CO2 and NO2 in schools within the Sentinel Schools Network of Catalonia during the COVID-19 era
Explore how the COVID-19 Sentinel Schools Network of Catalonia monitored CO2 and NO2 levels in classrooms, revealing key findings on ventilation and air quality in schools across Catalonia during the pandemic.
Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19
1 year after an acute COVID-19 episode, patients with either lung sequelae or long COVID show a stronger SARS-CoV-2-specific T-cell response than fully recovered individuals, suggesting persistent cell stimulation by residual viral reservoirs
Artículos
Ensayos
- 769685·Nuria Olvera et Al.- Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
- 779885·Ana Rodrigo-T,Jordi Giner,Lidia Perea,Jose Luis Merino,Núria Albacar,Belén Solarat,Diego Castillo,Rosa Faner,Alvar Agustí,Oriol Sibila. Predicting Early Hospital Readmissions in COPD Patients Using an Electronic Nose | Archivos de Bronconeumología
- 788772·Alvar Agustí et al. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial
Imagen obtenida en Canva Pro.